Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Glioblastoma multiforme Age: Adult Condition: Concomitant phase with focal radiotherapy |
Dose: Oral – 75 mg/m2 Frequency: once daily Duration: 42 days Note: Do not reduce dose during concomitant phrase but interrupt or discontinue therapy depending on toxicity. Continue if absolute neutrophil count (ANC) greater than 1.5x109/L, thrombocyte count greater than 100x109/L and Common Toxicity Criteria (CTC) non-haematological toxicity less than Grade 1 (except for alopecia, nausea and vomiting). |
|
Indication: Glioblastoma multiforme Age: Adult Condition: Monotherapy (Cycle 1) starting 4 weeks after concomitant phase |
Dose: Oral – 150 mg/m2 Frequency: once daily Duration: 5 days followed by a 23 day break (1 cycle) |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Recurrent or progressive malignant gliomas Age: greater than 3 years Condition: Previously untreated with chemotherapy |
Dose: Oral – 200 mg/m2 Frequency: once daily Duration: for 5 days, followed by a 23 day break (1 cycle) |
|
Indication: Recurrent or progressive malignant gliomas Age: greater than 3 years Condition: Previously treated with chemotherapy |
Dose: Oral – 150 mg/m2 Frequency: daily Duration: for 5 days followed by 23 day break (1 cycle) Note: increased to 200 mg/m2 for the 2nd cycle if there is no haematological toxicity |
Administration
- Take on empty stomach
- Take 1 hour before meals
Side Effect
- Alopecia (55-69%)
- Lymphopenia (55%)
- Nausea (53%)
- Vomiting (42%)
- Headache (41%)
- Fatigue (34%)
- Constipation (33%)
- Anorexia (9-27%)
- Convulsions (23%)
- Thrombocytopenia (19%)
- Rash (8-19%)
- Hemiparesis (18%)
- Diarrhea (16%)
- Neutropenia (14%)
- Fever (13%)
- Asthenia (13%)
- Dizziness (12%)
- Peripheral edema (11%)
- Viral infections (11%)
- Amnesia (10%)
- Insomnia (10%)
- Abdominal pain (5-9%)
- Ataxia (8%)
- Back pain (8%)
- Paresis (8%)
- URI (8%)
- Urinary incontinence (8%)
- UTI (8%)
- Abnormal vision (5-8%)
- Pruritus (5-8%)
- Breast pain (6%)
- Depression (6%)
- Confusion (5%)
- Myalgia (5%)
- Weight gain (5%)
- Anemia (4%)
- Erythema (1%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Valproic acid, Other myelosuppressive agents
|
Interactions mentioned but effects not specified
|
|
Valproic acid, Other myelosuppressive agents
|
Interactions mentioned but effects not specified
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Severe Myelosuppression
|
Can dangerously lower blood cells
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store at 15-30° C.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.